Saturday, July 11, 2026

pharma · Arginase 1 deficiency (ARG1-D)

Immedica Pharma AB

Immedica Pharma AB clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Stockholm, SE HQ
2018 Founded
179 Employees
EMA registrant Type
Company details
Status
Public
HQ
Stockholm, SE
Founded
2018
Employees
179
Programs
1
Drugs
4
Patents
0
Intelligence · Clinical Programs

Immedica Pharma AB projects

1 ClinicalTrials.gov programs sponsored by Immedica Pharma AB.

Immedica Pharma AB has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Loargys 5 mg/ml solution for injection/infusion

    Immedica Pharma AB

    Arginase 1 deficiency (ARG1-D)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Immedica Pharma AB have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.